Blog

BOSTON, June 23, 2025 /<a data-mce-href="https://www.prnewswire.com/news-releases/toby-urine-test-completes-participation-in-2025-mayo-clinic-and-asu-alliance-for-health-care-medtech-accelerator-302488354.html?tc=eml_cleartime" href="https://www.prnewswire.com/news-releases/toby-urine-test-completes-participation-in-2025-mayo-clinic-and-asu-alliance-for-health-care-medtech-accelerator-302488354.html?tc=eml_cleartime" target="_blank" title="View official press release on PR Newswire" rel="noopener">PRNewswire</a>/ -- TOBY, Inc., a biotechnology company focusing on improving early cancer screening, today announced its completion of its participation in the Mayo Clinic and Arizona State University Alliance for Health Care MedTech Accelerator in Phoenix, AZ. Out of a global pool of applicants, only ten companies were selected for the 2025 cohort.&nbsp;TOBY is developing a noninvasive urine spectroscopy and Artificial Intelligence (AI) platform for early cancer detection. The technology analyzes unique molecular signatures to support early, accessible, and cost-effective screening using a urine test.The Mayo Clinic and Arizona State University MedTech Accelerator supports early-stage medical technology companies through access to clinical, academic, and commercial resources. Participating companies receive mentorship and strategic guidance during the program and remain connected through the MedTech Accelerator network."There is a critical need for screening methods that are accessible and affordable," said Matthew Laskowski, Chief Executive Officer of TOBY. "Participation in the MedTech Accelerator has been instrumental in advancing our technology and development strategy."According to the International Agency for Research on Cancer (IARC), global cancer incidence is projected to rise significantly between 2022 and 2045. In the United States, the National Cancer Institute estimates that over 2 million people will be diagnosed with cancer in 2025."Our goal is to support earlier detection, when treatment is most effective and the burden on patients and the healthcare system is reduced," said Dragan Sebišanović, Chief Science Officer of TOBY. "Our technology uses machine learning to help identify molecular patterns associated with early-stage cancer."To learn more, visit <a data-mce-href="http://www.toby.health" href="http://www.toby.health" title="Visit Toby’s homepage">Toby.health</a>. <h3>About TOBY, Inc.:&nbsp;</h3>TOBY, inspired by Sherlock Holmes's Bloodhound, is a BioTech startup focused on the early detection of cancer utilizing spectroscopy and Artificial Intelligence. TOBY has developed a single urine test that detects 10 cancers, representing over 60% of all new cases globally. This test identifies the unique molecular signature of cancer by combining the precision of spectroscopy, changes in biomarkers (VOCs), and cutting-edge computational algorithms to deliver early, easy, and affordable cancer screening.SOURCE TOBY, Inc.Media Contact: <a data-mce-href="mailto:Press@Toby.health" href="mailto:Press@Toby.health" title="Email the TOBY press team">Press@Toby.health</a>Investor Contact: <a data-mce-href="mailto:Investors@toby.health" href="mailto:Investors@toby.health" title="Email the TOBY investor team" data-mce-selected="inline-boundary">Investors@Toby.health</a>

Press

TOBY Urine Test completes participation in 2025 Mayo Clin...